| provide information about the presence of a disease or other health condition. It able to discriminate between patients who have a particular disease or condition and those who do not have it. | Screening and diagnostic tests |
| 1 conducted in asymptomatic
patients
2 conducted in
symptomatic patients. | 1 Screening
2 Diagnosis |
| A screening or diagnostic test can have
four basic types of outcomes. | 1 True Positive test
2 True Negative test
3 False Positive test
4 False Negative test |
| 1 result is one that detects a marker when the
disease is present.
2 result is one that does not detect the marker
when the disease is absent
3 result is
one that detects a marker when
the disease is absent
4 result is
one that does not detect a marker
when the disease is present. | 1 true positive test
2 true negative test
3 false positive test
4 false negative test |
| The effectiveness of a diagnostic (or screening) technology can be determined along a chain of inquiry that leads from technical capacity of a technology to changes in patient health outcomes to cost effectiveness (where relevant to decision makers), as follows | 1 Technical capacity
2 Diagnostic accuracy
3 Diagnostic impact
4 Therapeutic impact
5 Patient outcome
6 Cost effectiveness |
| 1 Does the
technology perform reliably and
deliver accurate information?
2 Does the
technology contribute to making
an accurate diagnosis? | 1 Technical capacity.
2 Diagnostic accuracy |
| 1 Do the diagnostic results influence use of other diagnostic technologies, e.g., does it replace other
diagnostic technologies?
2 Do the diagnostic findings influence the selection and delivery of treatment? | 1 Diagnostic impact
2 Therapeutic impact |
| 1 Does use of the diagnostic technology contribute to improved health of the patient?
2 Does use of the diagnostic technology improve the cost effectiveness of health care compared to alternative interventions? | 1 Patient outcome
2 Cost effectiveness |
| Expertise for Conducting HTA | Health professionals, Managers
of hospital, clinics, nursing
homes, etc, Pharmacists,
Laboratory technicians,
Biomedical and clinical
engineers, Patients and
community representatives,
Epidemiologists, Biostatisticians,
Economists, Social scientists,
Decision scientists, Ethicists,
Lawyers, Computer
scienticts/programmer,
Librarians/information specialists |
| Basic HTA Framework/steps in HTA
process | 1. Identify assessment topics
2.Specify the assessment problem or questions
3. Determine organizational locus or responsibility for assessment
4. Retrieve available relevant evidence
5. Generate or collect new evidence (as appropriate)
6. Appraise/interpret quality of the evidence
7. Integrate/synthesize evidence
8. Formulate findings and recommendations
9. Disseminate findings and recommendations
10. Monitor impact |
| Health technology Council: | 1 Core committee
2) 7 Subcommittees |
| HTA contributes to the achievement of
UHC by: | •Increasing transparency, accountability,
and equity
•Institutionalizing priority setting
mechanism on health technology
coverage
•Improving efficiency in allocation of
resources
•Negotiating better prices of health
technologies |
| 1 In the implementation of UHC law, HTAC
should prioritize the review of existing
health technologies within __ (years?) upon
their creation (from October 2019 to
October 2021)
1 In parallel, they will also accommodate the
assessment of new health technologies
which are proposed by the __ | 1 two years
2 DOH and
PhilHealth. |
| Steps in HTA process: | 1. Topic nomination
2. Topic Prioritization
3. Scoping and Protocol Development
4. Assessment
5. Evidence appraisal
6. Recommendation
7. Resolution
8. Decision
9. Dissemination |
| FOR THE FIRST TWO YEARS of the HTA
PROCESS IMPLEMENTATION; (from October 2019 to October 2021), the HTAC shall accept topic nominations from DOH and PhilHealth for the priority
assessments in accordance with the UHC Law | Nomination |
| Public health emergencies: (i)
bioterrorism; (ii) appearance of a
novel or previously controlled or
eradicated infectious agent or
biological toxin; (iii) a natural
disaster; (iv) a chemical attack or
accidental release; (v) a nuclear
attack or accident; or (vi) an
attack or accidental release of
radioactive materials | Prioritization |
| can be performed by either the
internal assessment team (i.e.,
HTA unit) or an external
assessment team that is a part of
the HTA research network that
will be created by the DOH and
DOST (Department of Science
and Technology). | Assessment |
| (Prior to submitting topic nomination)
HTAC will only
consider the use of these health
technologies within the approved
marketing authorization of the product in
the Philippines as certified by the FDA | Drugs and vaccines |
| if exempted from the current FDA
process of granting marketing
authorization, the technology sponsor shall
submit a Certificate of Free Sale (CFS)
issued by the regulatory authority from the
source country or other stringent regulatory
authority, which shall be validated by the
Philippine FDA | Medical devices |
| Criteria in making Recommendation: | •Responsiveness to disease magnitude,
severity, and equity
•Safety and effectiveness
•Household financial impact
•Cost-effectiveness
•Affordability and viability |
